Cargando…

Inhibition of myeloperoxidase enhances immune checkpoint therapy for melanoma

BACKGROUND: The presence of a highly immunosuppressive tumor microenvironment has limited the success of immune checkpoint therapy (ICT). Immune suppressing myeloid cells with increased production of reactive oxygen species are critical drivers of this immunosuppressive tumor microenvironment. Strat...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Tracy W, Gammon, Seth T, Yang, Ping, Ma, Wencai, Wang, Jing, Piwnica-Worms, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944647/
https://www.ncbi.nlm.nih.gov/pubmed/36805920
http://dx.doi.org/10.1136/jitc-2022-005837
_version_ 1784891961005572096
author Liu, Tracy W
Gammon, Seth T
Yang, Ping
Ma, Wencai
Wang, Jing
Piwnica-Worms, David
author_facet Liu, Tracy W
Gammon, Seth T
Yang, Ping
Ma, Wencai
Wang, Jing
Piwnica-Worms, David
author_sort Liu, Tracy W
collection PubMed
description BACKGROUND: The presence of a highly immunosuppressive tumor microenvironment has limited the success of immune checkpoint therapy (ICT). Immune suppressing myeloid cells with increased production of reactive oxygen species are critical drivers of this immunosuppressive tumor microenvironment. Strategies to limit these immune suppressing myeloid cells are needed to enhance response to ICT. METHODS: To evaluate the contribution of myeloperoxidase (MPO), a myeloid lineage-restricted enzyme and a major source of reactive oxygen species, to mediating ICT response, we compared treatment outcome and immune composition in wild-type, MPO-deficient (MPO(−/−)), and MPO inhibitor-treated wild-type mice using established primary melanoma models. RESULTS: Tumor growth and survival studies demonstrated that either host deficiency (MPO(−/−)) or pharmacological inhibition of MPO enhanced ICT response in two preclinical models of established primary melanoma in aged animals. The tumor microenvironment and systemic immune landscape underwent striking changes in infiltration of myeloid cells, T cells, B cells, and dendritic cells in MPO(−/−) mice; furthermore, a significant increase in myeloid cells was observed in ICT non-responders. The contribution of CD4(+) T cells and NK cells during ICT response also changed in MPO(−/−) mice. Interestingly, MPO enzymatic activity, but not protein, was increased in CD11b(+)Ly6G(+) myeloid cells isolated from marrow, spleen, and peritoneal cavities of mice bearing untreated melanoma, indicating systemic activation of innate immunity. Notably, repurposing MPO-specific inhibitors (verdiperstat, AZD5904) in combination with ICT pointedly enhanced response rates above ICT alone. Indeed, long-term survival was 100% in the YUMM3.3 melanoma model on treatment with verdiperstat plus ICT. CONCLUSION: MPO contributes to ICT resistance in established melanoma. Repurposing MPO-specific inhibitors may provide a promising therapeutic strategy to enhance ICT response.
format Online
Article
Text
id pubmed-9944647
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-99446472023-02-23 Inhibition of myeloperoxidase enhances immune checkpoint therapy for melanoma Liu, Tracy W Gammon, Seth T Yang, Ping Ma, Wencai Wang, Jing Piwnica-Worms, David J Immunother Cancer Basic Tumor Immunology BACKGROUND: The presence of a highly immunosuppressive tumor microenvironment has limited the success of immune checkpoint therapy (ICT). Immune suppressing myeloid cells with increased production of reactive oxygen species are critical drivers of this immunosuppressive tumor microenvironment. Strategies to limit these immune suppressing myeloid cells are needed to enhance response to ICT. METHODS: To evaluate the contribution of myeloperoxidase (MPO), a myeloid lineage-restricted enzyme and a major source of reactive oxygen species, to mediating ICT response, we compared treatment outcome and immune composition in wild-type, MPO-deficient (MPO(−/−)), and MPO inhibitor-treated wild-type mice using established primary melanoma models. RESULTS: Tumor growth and survival studies demonstrated that either host deficiency (MPO(−/−)) or pharmacological inhibition of MPO enhanced ICT response in two preclinical models of established primary melanoma in aged animals. The tumor microenvironment and systemic immune landscape underwent striking changes in infiltration of myeloid cells, T cells, B cells, and dendritic cells in MPO(−/−) mice; furthermore, a significant increase in myeloid cells was observed in ICT non-responders. The contribution of CD4(+) T cells and NK cells during ICT response also changed in MPO(−/−) mice. Interestingly, MPO enzymatic activity, but not protein, was increased in CD11b(+)Ly6G(+) myeloid cells isolated from marrow, spleen, and peritoneal cavities of mice bearing untreated melanoma, indicating systemic activation of innate immunity. Notably, repurposing MPO-specific inhibitors (verdiperstat, AZD5904) in combination with ICT pointedly enhanced response rates above ICT alone. Indeed, long-term survival was 100% in the YUMM3.3 melanoma model on treatment with verdiperstat plus ICT. CONCLUSION: MPO contributes to ICT resistance in established melanoma. Repurposing MPO-specific inhibitors may provide a promising therapeutic strategy to enhance ICT response. BMJ Publishing Group 2023-02-17 /pmc/articles/PMC9944647/ /pubmed/36805920 http://dx.doi.org/10.1136/jitc-2022-005837 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Basic Tumor Immunology
Liu, Tracy W
Gammon, Seth T
Yang, Ping
Ma, Wencai
Wang, Jing
Piwnica-Worms, David
Inhibition of myeloperoxidase enhances immune checkpoint therapy for melanoma
title Inhibition of myeloperoxidase enhances immune checkpoint therapy for melanoma
title_full Inhibition of myeloperoxidase enhances immune checkpoint therapy for melanoma
title_fullStr Inhibition of myeloperoxidase enhances immune checkpoint therapy for melanoma
title_full_unstemmed Inhibition of myeloperoxidase enhances immune checkpoint therapy for melanoma
title_short Inhibition of myeloperoxidase enhances immune checkpoint therapy for melanoma
title_sort inhibition of myeloperoxidase enhances immune checkpoint therapy for melanoma
topic Basic Tumor Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944647/
https://www.ncbi.nlm.nih.gov/pubmed/36805920
http://dx.doi.org/10.1136/jitc-2022-005837
work_keys_str_mv AT liutracyw inhibitionofmyeloperoxidaseenhancesimmunecheckpointtherapyformelanoma
AT gammonsetht inhibitionofmyeloperoxidaseenhancesimmunecheckpointtherapyformelanoma
AT yangping inhibitionofmyeloperoxidaseenhancesimmunecheckpointtherapyformelanoma
AT mawencai inhibitionofmyeloperoxidaseenhancesimmunecheckpointtherapyformelanoma
AT wangjing inhibitionofmyeloperoxidaseenhancesimmunecheckpointtherapyformelanoma
AT piwnicawormsdavid inhibitionofmyeloperoxidaseenhancesimmunecheckpointtherapyformelanoma